Pharmacoeconomics of the myeloid growth factors: a critical and systematic review.

Publication Type:

Journal Article

Source:

PharmacoEconomics, Volume 30, Issue 6, p.497-511 (2012)

Keywords:

Antineoplastic Agents, Biosimilar Pharmaceuticals, Cost-Benefit Analysis, Drug Costs, Economics, Pharmaceutical, Europe, Fever, Granulocyte Colony-Stimulating Factor, Granulocyte-Macrophage Colony-Stimulating Factor, Humans, Neoplasms, NEUTROPENIA, United States

Abstract:

The pharmacoeconomics of the myeloid growth factors (MGFs) is an important topic that has received substantial attention in recent years. The use of the MGFs as primary prophylaxis to prevent febrile neutropenia (FN) has grown considerably over the past decade and professional guidelines regarding their use have broadened the settings in which these agents are indicated. Recent data also suggest a potential role for them in reducing infection-related and all-cause mortality. The cost and effectiveness of these agents will continue to gain visibility as companies pursue approval for biosimilar agents in the US, similar to their recent approval in Europe.